(lp0
S"Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics Motley Fool - Mar 21, 2017 If you enjoy cutting-edge medicine, Ionis Pharmaceuticals Inc  and Juno Therapeutics Inc  are two biotech stocks that belong on your radar.Ionis Pharmaceuticals Inc  Upgraded to Hold by Vetr Inc. - Chaffey BreezeA Look at Ionis Pharmaceuticals' Spinraza - Market Realist"
p1
aS"Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money Motley Fool - Mar 1, 2017 Ionis Pharmaceuticals  reported fourth-quarter earnings on Tuesday. The biotech has two drugs on the market, but given Kynamro's low sales and the fact that spinal muscular atrophy drug Spinraza only launched in late December, most of&nbsp;..."
p2
aS"Company Update : Here's Why Ionis Pharmaceuticals Inc Shares ... Smarter Analyst - Feb 28, 2017 Ionis Pharmaceuticals Inc  reported that it outperformed its financial guidance by ending 2016 with pro forma operating income of $25.8 million and $665.2 million in cash, cash equivalents and short-term investments.Ionis Pharmaceuticals  Beats on Q4 Earnings - Yahoo FinanceIonis Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 03 - Equities.com"
p3
aS'Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen ... PR Newswire  - Mar 6, 2017 CARLSBAD, Calif. and CAMBRIDGE, Mass., March 6, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. , today announced that the pivotal Phase 3 APPROACH study of volanesorsen met its&nbsp;...Why Ionis Pharmaceuticals Rallied 12% in February - Motley FoolIonis Pharmaceuticals, Inc. : Checking the Chart - The USA Commerce'
p4
aS'Why Ionis Pharmaceuticals Is Tumbling 10% Today Motley Fool - Mar 10, 2017 What happened. After highly regarded investment firm Goldman Sachs cut its rating on the company, Ionis Pharmaceuticals  shares dropped by more than 10% at 1:45 p.m. EST today.Analyst Activity  Goldman Sachs Group Inc Reiterates Neutral on Ionis ... - Market ExclusiveIonis Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 10 - Equities.com'
p5
aS"Ionis Exonerated, Buying Opportunity Created By Goldman Downgrade Seeking Alpha - Mar 13, 2017 Long-term investors should stiff-arm today's Goldman Sachs downgrade of Ionis Pharmaceuticals  from Neutral to Sell because analyst Salveen Richter has ignored recent evidence exonerating the platform of alleged toxicity."
p6
aS'SHAREHOLDER ALERT: Bronstein, Gewirtz &amp; Grossman, LLC Announces Investigation ... PR Newswire  - Mar 6, 2017 NEW YORK, March 6, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz &amp; Grossman, LLC is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc.  . Such investors are&nbsp;...'
p7
aS"Market Scout: Checking the Levels for Ionis Pharmaceuticals Inc  The Standard - 11 hours ago Ionis Pharmaceuticals Inc 's current 14-day Willams %R value has been spotted at -96.84. Values can span from 0 to -100."
p8
aS'SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ionis ... Yahoo Finance - Mar 8, 2017 Ionis reported 8 serious adverse events concerned with volanesorsen. If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.'
p9
aS'Ionis Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 17 Equities.com - Mar 17, 2017 Ionis Pharmaceuticals Inc.  traded on unusually high volume on Mar. 17, as the stock lost 3.6% to close at $40.22. On the day, Ionis Pharmaceuticals Inc. saw 3.11 million shares trade hands on 15,821 trades. Considering that the stock averages ...Just the Facts on Ionis Pharmaceuticals, Inc.  - StockNewsJournalStock Showing Surging Activity: Ionis Pharmaceuticals, Inc.  - HugoPress'
p10
a.